Eight months of HeartMate II device support without drug therapy

Thromboembolic complication rates of 20%–30% were initially a major limitation to the widespread use of left ventricular assist devices. The success of the HeartMate (Thoratec, Corp., Pleasanton, CA, USA) device has been partly due to the reduced incidence of thromboembolic events, although anticoag...

Full description

Bibliographic Details
Published in:Journal of the Practice of Cardiovascular Sciences
Main Authors: Kewal Krishan, Sean Pinney, Anelechi C Anyanwu
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2017-01-01
Subjects:
Anticoagulation
device thrombosis
HeartMate II
no drug therapy
noncompliance
Online Access:http://www.j-pcs.org/article.asp?issn=2395-5414;year=2017;volume=3;issue=2;spage=122;epage=124;aulast=Krishan

Internet

http://www.j-pcs.org/article.asp?issn=2395-5414;year=2017;volume=3;issue=2;spage=122;epage=124;aulast=Krishan

Similar Items